Robin Sherrington net worth and biography

Robin Sherrington Biography and Net Worth

Dr. Sherrington has served as our Executive Vice President, Strategy & Innovation since March 2019. Dr. Sherrington previously served as our Executive Vice President, Business & Corporate Development since March 2018, as our Senior Vice President, Business & Corporate Development since February 2012, as our Vice President, Business & Corporate Development from January 2010 to February 2012, and has held various positions in business development and other departments since joining us in March 2001. Prior to joining us, Dr. Sherrington worked at Pfizer, Inc., a global pharmaceutical company, as a neuroscientist from 1999 to 2001. Dr. Sherrington also previously served as Director of Neuroscience, from 1996 to 1999, at the biotechnology companies Axys Pharmaceuticals and Sequana Therapeutics. Prior to 1996 Dr. Sherrington was a post-doctoral fellow at University of Toronto and received his Ph.D. from the University College London, and his B.Sc. with honors from University of Reading.

What is Robin Sherrington's net worth?: The estimated net worth of Robin Sherrington is at least $321.06 thousand as of March 7th, 2024. Dr. Sherrington owns 8,398 shares of Xenon Pharmaceuticals stock worth more than $321,056 as of November 3rd. This net worth estimate does not reflect any other investments that Dr. Sherrington may own. Learn More about Robin Sherrington's net worth.
How do I contact Robin Sherrington?: The corporate mailing address for Dr. Sherrington and other Xenon Pharmaceuticals executives is 3650 Gilmore Way, Burnaby, BC, V5G 4W8. Xenon Pharmaceuticals can also be reached via phone at (604) 484-3300 and via email at [email protected]. Learn More on Robin Sherrington's contact information.
Has Robin Sherrington been buying or selling shares of Xenon Pharmaceuticals?: Robin Sherrington has not been actively trading shares of Xenon Pharmaceuticals over the course of the past ninety days. Most recently, Robin Sherrington sold 7,137 shares of the business's stock in a transaction on Thursday, March 7th. The shares were sold at an average price of $46.28, for a transaction totalling $330,300.36. Following the completion of the sale, the executive vice president now directly owns 8,398 shares of the company's stock, valued at $388,659.44. Learn More on Robin Sherrington's trading history.
Who are Xenon Pharmaceuticals' active insiders?: Xenon Pharmaceuticals' insider roster includes Sherry Aulin (CFO), Gillian Cannon (Director), Andrea DiFabio (Chief Legal Officer and Corporate Secretary), James Empfield (EVP), Steven Gannon (Director), Frank Holler (Director), Christopher Kenney (Insider), Ian Mortimer (President and Chief Executive Officer), Gary Patou (Director), Simon Pimstone (Director), Robin Sherrington (EVP), Dawn Svoronos (Director), and Christopher Von Seggern (Insider). Learn More on Xenon Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Xenon Pharmaceuticals?: In the last year, Xenon Pharmaceuticals insiders bought shares 2 times. They purchased a total of 45,000 shares worth more than $1,681,200.00. In the last year, insiders at the biopharmaceutical company sold shares 15 times. They sold a total of 381,589 shares worth more than $21,969,427.77. The most recent insider tranaction occured on September, 30th when CFO Thomas Patrick Kelly bought 15,000 shares worth more than $559,800.00. Insiders at Xenon Pharmaceuticals own 2.9% of the company. Learn More about insider trades at Xenon Pharmaceuticals.
Information on this page was last updated on 9/30/2026.

Robin Sherrington Insider Trading History at Xenon Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/7/2024	Sell	7,137	$46.28	$330,300.36	8,398
3/4/2022	Sell	21,710	$30.50	$662,155.00
5/28/2021	Sell	6,067	$18.81	$114,120.27	29,141

Robin Sherrington Buying and Selling Activity at Xenon Pharmaceuticals

Xenon Pharmaceuticals Company Overview

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.

Today's Range

Now: $38.23

$37.78

$39.00

50 Day Range

MA: $44.88

$33.49

$63.79

2 Week Range

Now: $38.23

$33.38

$72.66

Volume

1,246,633 shs

Average Volume

1,391,665 shs

Market Capitalization

$3.70 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.6